Generex Biotechnology Corporation (NASDAQ: GNBT), a biopharmaceutical company, has a diversified product portfolio designed to deliver innovative products to treat patients with cancer. DNA/RNA-based Medicines and Small Molecules are the two major programs that anchor the Company’s research platform. Ganite® (gallium nitrate injection) is the company’s leading drug in the Small Molecule program. Ganite is exclusively marketed in the U.S. to treat symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. For further information, visit the Company’s web site at www.genta.com.
- 17 years ago
QualityStocks
Generex Biotechnology Corporation (NASDAQ: GNBT)
Tags Rodman & Renshaw
Related Post
-
Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) Set to Capitalize on North American Push to Secure Rare Earth Supply Chains
Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid…
-
SPARC AI Inc. (SPAIF) Is Developing a Target Acquisition and Navigation System That Doesn’t Rely on GPS
SPARC AI provides GPS-free autonomous navigation and target acquisition systems for drones and other edge…
-
A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) Expands Leadership, Global Presence in Intelligent Retail Solutions
A2Z Cust2Mate Solutions announced key additions to its global sales leadership team to accelerate growth…